In­dus­try wants new Eu­ro­pean phar­ma makeover to in­crease the con­ti­nen­t's at­trac­tive­ness for R&D

Lat­er this year, the Eu­ro­pean Com­mis­sion is plan­ning to re­lease a ma­jor pro­pos­al to over­haul the con­ti­nent’s gen­er­al phar­ma­ceu­ti­cal leg­is­la­tion, as part of plans to boost the sec­tor’s glob­al com­pet­i­tive­ness and cre­ate a reg­u­la­to­ry en­vi­ron­ment that’s more at­trac­tive for in­no­va­tion and in­vest­ment.

Af­ter re­veal­ing a wide range of ma­jor is­sues that the com­mis­sion seeks to ad­dress, re­cent­ly re­leased stake­hold­er com­ments tend to agree with the com­mis­sion on its plans to at­tack un­met med­ical needs and mar­ket fail­ures, an­timi­cro­bial re­sis­tance, drug com­pe­ti­tion and short­ages, and the speed of tech progress, such as with ge­nom­ic se­quenc­ing, gene edit­ing tech­nolo­gies or AI.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER